September 24th, 2012
Selections from Richard Lehman’s Literature Review: September 24th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include papers on punishing health care fraud, how physicians interpret research funding disclosures, and the association between BP and mortality in those newly diagnosed with type-2 diabetes.
September 24th, 2012
Stress and Coronary Heart Disease: What Role Does Gender Play?
Xiao Xu, PhD
Xiao Xu examines the unique stressors – both at home and at work – that women and men may face.
September 21st, 2012
Apixaban (Eliquis) For Atrial Fibrillation Gets Positive European Recommendation
Larry Husten, PHD
The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation. The drug is already approved in Europe for the prevention of venous thromboembolic events following hip or knee replacement surgery. The drug has not yet been approved in the United States. Here is the CHMP-proposed indication […]
September 20th, 2012
Why I Applaud the Skeptical Physicians
Joseph S. Ross, MD, MHS
Is skepticism of industry-funded trials warranted even when they are designed, conducted, and reported with the utmost rigor?
September 19th, 2012
Certification Exam Prep: An FAQ
Benjamin Howard Freed, MD
Your questions about board exam prep entertained and answered.
September 17th, 2012
Selections from Richard Lehman’s Literature Review: September 17th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include surgical vs. lifestyle treatment for type-2 diabetes, omega-3 fatty-acid supplementation and the risk for major CVD events, FAME 2, using high-sensitivity cardiac troponin T for one-hour rule-out or rule-in of acute MI, and the timing of acute MI in patients having total hip or knee replacement.
September 13th, 2012
Meta-Analysis Links Stress at Work and Heart Disease
Larry Husten, PHD
A new study in the Lancet provides the best evidence yet that work-related stress and, in particular, job strain — “the combination of high job demands and low control at work” — plays a small but important role in causing heart disease. In order to address the limitations of previous studies on this topic, including […]
September 13th, 2012
A Manhattan Project to End the Obesity Epidemic
Larry Husten, PHD
A newly launched nonprofit organization, the Nutrition Science Initiative, will try to find an answer to the question, “What should we eat to be healthy?” Called NuSI (pronounced “new see”) for short, the organization is nothing if not ambitious: its goal is to seek “the end of fad diets and high obesity rates.” NuSI’s founders are Gary Taubes and Peter Attia. Taubes […]
September 12th, 2012
Study Predicts Renal Denervation Will Be Cost-Effective in Resistant Hypertension
Larry Husten, PHD
Renal denervation (RDN) for resistant hypertension may be cost-effective and may provide long-term clinical benefits, according to a new analysis published in the Journal of the American College of Cardiology. Benjamin Geisler and colleagues developed a model to predict the impact of the Medtronic Symplicity RDN system in patients with resistant hypertension. Over 10 years, according […]
September 10th, 2012
Selections from Richard Lehman’s Literature Review: September 10th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the safety risks of drugs that have gone through the FDA’s expedited approval program, a Framingham Heart Study paper on aortic stiffness in the elderly, and using CMR to detect previously undetected MI in older adults.
NEJM Journal Watch — Recent Cardiology Articles- Oral Semaglutide Approved to Lower Cardiovascular Risk in High-Risk Patients with Type 2 Diabetes
- Covid-19 Vaccines Improve Heart Outcomes
- Detecting Atrial Fibrillation After Transient In-Hospital Episodes
- Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
- Amyloid in the Heart